#25: CGXP Ceragenix and Hyphens Enter Into Distribution and Supply Agreement for EpiCeram® Hyphens to Market and Sell in Southeast Asia Ceragenix Pharmaceuticals, Inc.(“Ceragenix”) (OTCBB:CGXP), a medical device company focused on infectious disease and derm
Hyphens to Market and Sell in Southeast Asia
Ceragenix Pharmaceuticals, Inc.(“Ceragenix”) (OTCBB:CGXP social networks), a medical
device company focused on infectious disease...
Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced that Steven Porter, its Chairman and Chief Executive...
DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) today announced that Dr. Paul B. Savage, a Reed M. Izatt Professor of Chemistry and Biochemistry at Brigham Young...
DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today reported it has completed the...
DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical
company focused on infectious disease and dermatology, today reported it
has enrolled the...
DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), an emerging
biopharmaceutical company focused on infectious disease and dermatology,
reports it has completed...
DENVER--(BUSINESS WIRE)--Sept. 20, 2006--Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease and dermatology, today announced that Dr. Paul Savage, Professor...
#18: CGXP News Ceragenix Pharmaceuticals Initiates EpiCeram(R) Clinical Trial; EpiCeram(R) to be Compared to Mid-Strength Steroid in Children with Moderate-to-Severe Eczema
DENVER--(BUSINESS WIRE)--Aug. 14, 2006--Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease and dermatology, today announced that it has begun enrolling...
#17: CGXP News Ceragenix Pharmaceuticals Provides Mid-Year Update; Company Commencing Post-510k Clearance Studies for EpiCeram(R) to Support Current Partnering Discussions
DENVER--(BUSINESS WIRE)--July 31, 2006--Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease and dermatology, today announced that research by Dr. Emiko Isogai...
#15: CGXP News Research on Use of Ceragenins(TM) As Potential Therapy for Cystic Fibrosis Related Infections and Other Diseases to be Presented at ICAAC 2006
DENVER--(BUSINESS WIRE)--July 26, 2006--Ceragenix Pharmaceuticals, Inc. a biopharmaceutical company focused on infectious disease and dermatology, today announced that the American Society of...
#14: CGXP News Ceragenix Obtains IRB Approval for Eczema Clinical Study; Study to Compare EpiCeram(R) to Mid-Strength Topical Steroid in Treatment of Children with Moderate-to-Severe Eczema
DENVER--(BUSINESS WIRE)--June 27, 2006--Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease and dermatology, today announced that it has received...
#13: CGXP News Ceragenix Enters Into Research and Development Agreement; Drugs Targeted Toward Prevention of Influenza Infection and Eradication of MRSA Bacterial Colonization
DENVER--(BUSINESS WIRE)--June 21, 2006--Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease and dermatology, today announced that it has entered into a...
Centers for Disease Control and Prevention (CDC) and Ceragenix Enter into a Cooperative Research and Development Agreement (CRADA)
CRADA to Evaluate the Efficacy of Ceragenix's Ceracide(TM)...
#11: CGXP News In Vitro Study Results Show Ceragenix's Lead Antibiotic Compound Has Greater Bactericidal Activity against Potentially Lethal Bacterial Infections Than Leading Commonly-Prescribed Antibiotic Treatments
DENVER--(BUSINESS WIRE)--Dec. 21, 2005--Studies presented at the 45th Interscience Conference of Antimicrobial Agents and Chemotherapy ("ICAAC") demonstrated that Ceragenix Pharmaceuticals, Inc.'s...
